At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 12-12 16:00:00 EST
0.6088
-0.0182
-2.90%
盘后0.5914
-0.0174-2.86%
19:57 EST
High0.6269Low0.5902Vol304.44K
Open0.6233D1 Closing0.6270Amplitude5.85%
Mkt Cap12.99MTradable Cap10.20MTotal Shares21.33M
T/O184.55KT/O Rate1.82%Tradable Shares16.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum
THOMSON REUTERS  ·  12-03
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum
Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy
Reuters  ·  12-02
Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging
THOMSON REUTERS  ·  12-02
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging
Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows
Reuters  ·  12-02
Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows
Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
THOMSON REUTERS  ·  12-02
Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease
Reuters  ·  11-19
Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
THOMSON REUTERS  ·  11-19
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)
Longeveron granted U.S. patent for administration of MSCs
TIPRANKS  ·  11-12
Longeveron granted U.S. patent for administration of MSCs
Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
Reuters  ·  11-12
Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy
THOMSON REUTERS  ·  11-12
Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy
Longeveron Inc - Patent Rights in U.S. Through 2038
THOMSON REUTERS  ·  11-12
Longeveron Inc - Patent Rights in U.S. Through 2038
Longeveron Directors Khoso Baluch and Neha Motwani Resign
Reuters  ·  11-12
Longeveron Directors Khoso Baluch and Neha Motwani Resign
Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments
TIPRANKS  ·  11-07
Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments
Roth MKM Reaffirms Their Buy Rating on Longeveron (LGVN)
TIPRANKS  ·  11-05
Roth MKM Reaffirms Their Buy Rating on Longeveron (LGVN)
Longeveron Inc - on Track for Elpis Ii Results in Q3 2026 - SEC Filing
THOMSON REUTERS  ·  11-05
Longeveron Inc - on Track for Elpis Ii Results in Q3 2026 - SEC Filing
Cellular therapy developer Longeveron's Q3 net loss widens
Reuters  ·  11-05
Cellular therapy developer Longeveron's Q3 net loss widens
Longeveron Q3 EPS USD -0.39
Reuters  ·  11-05
Longeveron Q3 EPS USD -0.39
Longeveron Q3 Operating Expenses USD 7.435 Million
THOMSON REUTERS  ·  11-05
Longeveron Q3 Operating Expenses USD 7.435 Million
Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate
Benzinga  ·  11-05
Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
GlobeNewswire  ·  10-28
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--